Exact Mass: 450.0951

4-((2-Chloroethyl)(2-mesyloxyethyl)amino)benzoylglutamic acid

2-({4-[(2-chloroethyl)[2-(methanesulfonyloxy)ethyl]amino]phenyl}formamido)pentanedioic acid

C17H23ClN2O8S (450.0864)

Tedizolid phosphate

[(3-{3-fluoro-4-[6-(2-methyl-2H-1,2,3,4-tetrazol-5-yl)pyridin-3-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methoxy]phosphonic acid

CONFIDENCE Transformation product, tentative ID (Level 2b); INTERNAL_ID 2203

TW-95a

(E)-3-[4-hydroxy-3-methoxy-5-[(4R)-6-methoxy-4-(sulfomethyl)chroman-3-yl]phenyl]prop-2-enoic acid|tarvanol A

C21H22O9S (450.0984)

2,4-O-Methylene,1,5-dibenzoyl,3-mesyl-Ribitol

C21H22O9S (450.0984)

gaboroquinones

4-(6-(BENZOYLOXY)BENZO[B]THIOPHEN-2-YL)PHENYL BENZOATE

C28H18O4S (450.0926)

1,3,6,8,10,13,16,19-OCTAAZABICYCLO[6.6.6]EICOSANECOBALT TRICHLORIDE

C12H30Cl3CoN8 (450.0991)

Tedizolid Phosphate

A four-component ring assembly consisting of 5-(phosphooxymethyl)-1,3-oxazolidin-2-one, fluorobenzene, pyridine and 2-methyltetrazole rings joined in sequence. The prodrug of tedizolid, used for the treatment of acute bacterial skin infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic

s-(2-hydroxy-5-nitrobenzyl)-6-thioguanosine

C17H18N6O7S (450.0958)

cmda

C17H23ClN2O8S (450.0864)

[(5R)-3-{3-Fluoro-4-[6-(1-methyl-1H-tetrazol-5-yl)-3-pyridinyl]phenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl dihydrogen phosphate

C17H16FN6O6P

Tris(4-methylphenyl)sulfonium hexafluorophosphate

C21H21F6PS (450.1006)

2,4,6-Tris(4-fluorophenyl)pyrylium tetrafluoroborate

C23H14BF7O (450.1026)

Tedizolid phosphate

[(3-{3-fluoro-4-[6-(2-methyl-2H-1,2,3,4-tetrazol-5-yl)pyridin-3-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl)methoxy]phosphonic acid

S-[(1R,2S)-1-(2-chlorophenyl)-2-(4-fluorophenyl)-1-hydroxy-3-(1H-1,2,4-triazol-1-yl)propan-2-yl]-L-cysteine

C20H20ClFN4O3S (450.0929)

Gaboroquinone A

An anthraquinone that is anthracene-9,10-dione substituted by a 3-acetyl-4,6-dihydroxy-2-methoxyphenyl moiety at position 1, hydroxy groups at positions 4 and 5 and a hydroxymethyl group at position 2. Isolated from the roots of Bulbine frutescens, it exhibits antiplasmodial and antitrypanosomal activities.

(1s,4r,5r,9r,11s,14r,19r)-5,15-dihydroxy-1,11-bis(methylsulfanyl)-3,13-diazapentacyclo[11.7.0.0³,¹¹.0⁴,⁹.0¹⁴,¹⁹]icosa-6,16-diene-2,8,12,18-tetrone

8,19-dihydroxy-1,12-bis(methylsulfanyl)-6,17-dioxa-3,14-diazaheptacyclo[12.8.0.0³,¹².0⁴,¹⁰.0⁵,⁷.0¹⁵,²¹.0¹⁶,¹⁸]docosa-9,20-diene-2,13-dione

6-{[3-(2,4-dihydroxy-6-methylbenzoyl)-4,5,7-trihydroxynaphthalen-2-yl]methyl}-4-hydroxypyran-2-one

(1s,4r,5r,9r,11s,14r,15s,19r)-5,15-dihydroxy-1,11-bis(methylsulfanyl)-3,13-diazapentacyclo[11.7.0.0³,¹¹.0⁴,⁹.0¹⁴,¹⁹]icosa-6,16-diene-2,8,12,18-tetrone

5,15-dihydroxy-1,11-bis(methylsulfanyl)-3,13-diazapentacyclo[11.7.0.0³,¹¹.0⁴,⁹.0¹⁴,¹⁹]icosa-6,16-diene-2,8,12,18-tetrone

(1r,4s,5r,7s,8s,12r,15s,16r,18s,19s)-8,19-dihydroxy-1,12-bis(methylsulfanyl)-6,17-dioxa-3,14-diazaheptacyclo[12.8.0.0³,¹².0⁴,¹⁰.0⁵,⁷.0¹⁵,²¹.0¹⁶,¹⁸]docosa-9,20-diene-2,13-dione

1-(3-acetyl-2,6-dihydroxy-4-methoxyphenyl)-4,5-dihydroxy-2-(hydroxymethyl)anthracene-9,10-dione